Do you need a license to sell peptides in Washington?

There is no single credential called a peptide license. What a business buyer actually faces is a stack of separate questions — how the entity is registered, whether the activity looks like drug or device distribution to a regulator, whether a professional board has jurisdiction over the business model, and whether the inventory and the marketing around it stay inside the research-use-only lane. Each of those questions is answered by a different authority, and the answer changes completely depending on whether you are a reseller moving research materials to research buyers or an operator working inside a licensed healthcare context. This article describes the questions and the procedural consequences of getting them wrong. It is informational, not legal advice — the specifics belong to your attorney and to the relevant state board.

Why one answer never fits every buyer

The reason nobody can hand you a yes or no is that the phrase 'selling peptides' collapses at least four different business activities into one sentence. A company that imports bulk material and resells it to laboratories is doing something different from a company that private-labels research vials for an online storefront, which is different again from a clinic-adjacent business operating under professional licensure. Regulators do not evaluate the word 'peptide.' They evaluate what the product is represented to be, who it is sold to, and what the surrounding claims say it is for.

That is why the useful work happens before you ever look at a license application. You have to describe your own model in specific terms — what you buy, what you label, who your customer is, what your website says, and what your invoice says — and then bring that description to someone qualified to map it onto the frameworks that apply to you. A supplier cannot do that mapping for you, and any supplier who claims they can has told you something important about how they handle compliance generally.

The four questions that actually decide your answer

These are the questions worth resolving in order, with the right party for each. Bring documents, not hypotheticals — regulators and attorneys give sharper answers to a described business than to a general one.

Notice that three of the four rows depend on documents you control. That is the practical point: your licensing position is not fixed by the compound. It is largely determined by choices you make about labeling, customer qualification, and language — choices a regulator can read directly off your own website.

What research-use-only actually constrains

Research-use-only is not a disclaimer you paste into a footer. It is a description of what the material is and how it may be represented, and it only holds up when every artifact your business produces agrees with it. That consistency is the whole mechanism.

In practice it means the label, the invoice, the product page, the email sequence, and the sales conversation all describe the same thing: a compound supplied for laboratory research, not for human or animal consumption. It means no dosing information anywhere in your funnel, no administration guidance, no before-and-after framing, and no language that describes a person receiving the compound. It means you do not bundle supplies alongside compounds in a way that assembles an implied use kit — that pairing is read as intent, regardless of what the disclaimer says.

The procedural consequence of drift is what most operators underestimate. Research-use-only status is not revoked by a letter; it simply stops describing your business, and then the frameworks that apply to something else start applying to you. Once your marketing has characterized a compound as something people take, the question in front of you is no longer whether you needed a business registration. It is whether you have been operating inside a different regulatory category entirely, with a documented trail of your own copy as the evidence. That is why compliance reviews of your own site are cheaper than compliance defenses.

This also shapes how you should read supplier behavior. If a wholesaler is willing to describe research compounds in clinical language, volunteer usage guidance, or quote you on anything framed as a consumer health product, they are not being helpful. They are showing you the standard they hold themselves to — and their copy tends to end up in your copy.

Where research evidence fits, and where it does not

Buyers reasonably want to know what the science says about the compounds they stock. The honest framing is that published research on many peptide compounds is preliminary, and that studies indicate or research suggests certain mechanisms of interest without establishing anything approved for human use. Those two sentences are usable. What is not usable is converting a study into an implied benefit for your customer's customer.

For a reseller, the durable rule is that scientific interest belongs in a research context and never in a claim. You can accurately say that a compound is the subject of ongoing investigation. You cannot say it does anything for anyone, and you cannot let a citation do that work implicitly. Nothing sold in this category is an FDA-approved drug, and no supplier can make it one by describing it well.

The diligence that separates a real supplier from a storefront

Once you have your own lane defined, supplier evaluation becomes concrete. The documents you need are the ones that let you answer a question from a buyer, an auditor, or your own attorney without calling anyone.

Ask for a batch-specific certificate of analysis for the exact lot you would receive, not a representative sample from an unrelated run. Ask which analytical methods were used and what the panel actually covers, because purity by one method is not the same as purity across contamination categories. Ask whether COAs are published where you and your customers can read them, or whether they are provided on request, charged for separately, or simply described as available. A supplier that treats lab results as a paid add-on has told you what those results are worth to them.

Then look at the commercial mechanics. Is pricing visible and tiered, or does every quote require a conversation designed to price you individually? Where does fulfillment originate, and what happens when a lot fails testing? Who is your contact when an order arrives short? None of these are exotic requests. They are the baseline you would apply to any other inventory category, and the fact that this industry often tolerates less is exactly why applying them is an advantage.

Questions to bring to your attorney and your state board

Go in with a written model description and this list. The goal is not reassurance; it is a documented answer you can act on.

• Given how I describe and label these products, which registration or licensing frameworks apply to my entity?
• Does my customer base — who I sell to and how I verify them — change that answer?
• What customer qualification or attestation records should I keep, and for how long?
• What specific language on my site or invoices would move me out of the research-use-only lane?
• If I private-label, what labeling obligations follow me as the brand of record?
• Which agency or board would have jurisdiction over my model, and is an advisory opinion available?

Where state specifics matter, they vary, and general summaries are not a substitute for confirmation. In most cases the practical sequence is counsel first, then the board, then your supplier — because your supplier's documentation should support the position your counsel defines, not define it.

What Real Peptides does differently

Real Peptides supplies research-use-only compounds to businesses through its Wholesale Partner Program, and the program is built around the documentation a buyer needs for diligence.

Every compound is tested to 99%+ HPLC purity. Testing runs as a six-panel batch analysis, so purity is assessed alongside additional contamination categories rather than by a single method. Certificates of analysis are publicly verifiable — a partner or their customer can check the lab results directly rather than requesting them, paying for them, or accepting a description of them. Fulfillment is handled from within the US, with a stated 5–7 day fulfillment window. Pricing tiers are structured and disclosed rather than negotiated per buyer behind a form.

Access runs through a three-step wholesale application: submit your business details, get reviewed for qualification, then order at partner pricing. The review step exists because a wholesale program that qualifies nobody is a retail catalog with a discount code, and buyers who care about documentation generally prefer suppliers whose partner base is vetted.

What Real Peptides does not do is take a position on your licensing. No supplier can, and the ones who offer to should worry you more than the ones who decline.

If you have defined your model, confirmed your position with counsel, and want a supplier whose lab documentation stands up to the questions your own customers will ask, the qualification path is the wholesale application — bring your entity details and your intended catalog, and the review will tell you where you stand.

For more on program structure and pricing tiers, see the wholesale peptides program overview; when you are ready to be reviewed, apply for a wholesale account. For the broader framework behind this topic, read do you need a license to sell peptides.